TY - JOUR
T1 - Forced degradation study of thiocolchicoside: Characterization of its degradation products
AU - DEL GROSSO, Erika
AU - APRILE, SILVIO
AU - GROSA, Giorgio
PY - 2012
Y1 - 2012
N2 - Thiocolchicoside (TCC, N-[1,2-dimethoxy-10-methylsulphanyl-9-oxo-3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydropyran-2-yloxy)-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-acetamide) was subjected to hydrolytic, oxidative, and photolytic stresses. TCC underwent degradation in acidic, basic, and oxidative conditions, while it was stable toward other stress conditions. The degradation products (DPs) were detected and their separation was achieved on a SGE Wakosil C18RS 5μm (250*4.6mm; SGE) column employing a gradient LC-MS method for a total time of analysis of 18min. The mass fragmentation pathways of both thiocolchicoside and its degradation products were established using LC-MS experiments assigning the structures to the DPs. In particular, five DPs were identified as: D1SO (N-[1,2-dimethoxy-10-methylsulphoxide-9-oxo-3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydropyran-2-yloxy)-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-acetamide), D1SO 2 (N-[1,2-dimethoxy-10-methylsulphone-9-oxo-3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydropyran-2-yloxy)-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-acetamide), D2 ([1,2-dimethoxy-10-methylsulphanyl-9-oxo-3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydropyran-2-yloxy)-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amine), D3 (N-[1,2-dimethoxy-3-hydroxy-10-methylsulphanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-acetamide or 3-O-demethylthiocolchicine), D4 ([1,2-dimethoxy-3-hydroxy-10-methylsulphanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amine or N-deacetyl-3-O-demethylthiocochicine). Moreover, the structures of DPs were confirmed by synthesis of the reference standards which were fully characterized by MS, NMR, IR analyses. Finally a comprehensive degradation scheme of TCC was proposed allowing to outline D1SO and D3 as the indicators of its stability for oxidative and hydrolytic stress conditions.
AB - Thiocolchicoside (TCC, N-[1,2-dimethoxy-10-methylsulphanyl-9-oxo-3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydropyran-2-yloxy)-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-acetamide) was subjected to hydrolytic, oxidative, and photolytic stresses. TCC underwent degradation in acidic, basic, and oxidative conditions, while it was stable toward other stress conditions. The degradation products (DPs) were detected and their separation was achieved on a SGE Wakosil C18RS 5μm (250*4.6mm; SGE) column employing a gradient LC-MS method for a total time of analysis of 18min. The mass fragmentation pathways of both thiocolchicoside and its degradation products were established using LC-MS experiments assigning the structures to the DPs. In particular, five DPs were identified as: D1SO (N-[1,2-dimethoxy-10-methylsulphoxide-9-oxo-3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydropyran-2-yloxy)-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-acetamide), D1SO 2 (N-[1,2-dimethoxy-10-methylsulphone-9-oxo-3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydropyran-2-yloxy)-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-acetamide), D2 ([1,2-dimethoxy-10-methylsulphanyl-9-oxo-3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydropyran-2-yloxy)-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amine), D3 (N-[1,2-dimethoxy-3-hydroxy-10-methylsulphanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-acetamide or 3-O-demethylthiocolchicine), D4 ([1,2-dimethoxy-3-hydroxy-10-methylsulphanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amine or N-deacetyl-3-O-demethylthiocochicine). Moreover, the structures of DPs were confirmed by synthesis of the reference standards which were fully characterized by MS, NMR, IR analyses. Finally a comprehensive degradation scheme of TCC was proposed allowing to outline D1SO and D3 as the indicators of its stability for oxidative and hydrolytic stress conditions.
UR - https://iris.uniupo.it/handle/11579/13778
M3 - Article
SN - 0731-7085
VL - 61
SP - 215
EP - 223
JO - Journal of Pharmaceutical and Biomedical Analysis
JF - Journal of Pharmaceutical and Biomedical Analysis
ER -